NCT04757363 2026-03-04
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT04787341 2026-02-02
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT05672316 2026-01-28
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04781192 2026-01-23
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05830084 2026-01-06
REGO-INTER-EWI
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Active not recruiting
NCT03829462 2025-11-21
NEXT-REGIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Active not recruiting
NCT04803877 2025-10-31
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Active not recruiting
NCT02389244 2025-09-16
REGOBONE
UNICANCER
Phase 2 Active not recruiting
NCT02657551 2025-09-11
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05194293 2025-09-04
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03657641 2025-07-04
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Active not recruiting
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting